FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 603 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance MOST POPULAR A tribute to Professor Gordon McVie February 18, 2021 Four randomized prospective degree compared 90 days regarding neoadjuvant ADT observed... July 21, 2023 Inequalities cause 2,000 extra cancer cases in Wales June 8, 2023 74 & 75-Year-Old Sweethearts Get Married In ICU In Wake Of... February 10, 2022 Load more HOT NEWS How Receiving My Own Cancer Diagnosis Changed My Perspective on Caring... Researchers at Purdue Create Filler That May Help Regenerate Tissue in... Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did... Pancancer Activity of Dabrafenib Plus Trametinib in Patients with BRAFV600E-Mutated Rare...
